| 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 中国生物制药 | 谢炘 | 好仓 | 3.60 亿股 | 3.61 亿股 | 1.92%(最新) | | (01177) | | | | | 1.92%(前次) | 备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 智通财经APP获悉，中国生物制药(01177)于2025年12月25日进行了最新股东权益披露。 ...

智通财经APP获悉，香港联交所最新资料显示，12月24日，副总裁兼执行董事谢炘增持中国生物制药 (01177)100万股，每股作价6.4068港元，总金额为640.68万港元。增持后最新持股数目约为3.61亿股，最 新持股比例为1.92%。 ...

香港联交所最新资料显示，12月24日，副总裁兼执行董事谢炘增持中国生物制药(01177)100万股，每股 作价6.4068港元，总金额为640.68万港元。增持后最新持股数目约为3.61亿股，最新持股比例为1.92%。 ...

Group 1: Industry Overview - In October, the total sales of pharmaceutical products in mainland China decreased by 3% year-on-year, a significant drop from the 6.8% growth in September [1] - Hospital channel sales fell by 3.3% year-on-year, compared to a 7.1% increase in the previous month [1] - Retail channel sales remained flat year-on-year, a slowdown from the 2.4% growth in September [1] Group 2: Company Performance - Hansoh Pharmaceutical (03692) recorded the highest year-on-year growth among peers in October at 8.6%, with most key products showing double-digit month-on-month growth, except for PEG-loxenatide [1] - The report maintains a "Buy" rating for Hansoh Pharmaceutical with a target price of HKD 45 [1] - Hengrui Medicine (01276) faced pressure on multiple key products, with total sample sales growing by only 2% year-on-year in October, and specific products like butorphanol, ioversol, and sevoflurane seeing declines of 49.1%, 0.5%, and 10.8% respectively [1] - Hengrui's A-share target price is set at RMB 57.7, with a "Underperform" rating [1] Group 3: Additional Company Insights - China Biologic Products (01177) showed a mixed performance in October, with core products anlotinib and glycyrrhizic acid growing by 6.5% and 4.4% year-on-year, while budesonide and esomeprazole saw declines of 28.5% and 39.4% respectively [2] - The revenue forecasts for 2026 and 2027 were lowered by 0.2% and 0.4% respectively due to the sales performance, with the target price adjusted from HKD 9.4 to HKD 8.3, while maintaining a "Buy" rating based on pipeline potential [2] - CSPC Pharmaceutical Group (01093) continued to experience low sales for several key drugs, maintaining an "Underperform" rating with a target price of HKD 7.2 [2]

Core Viewpoint - The report from Bank of America indicates a significant decline in the sales of the pharmaceutical industry in mainland China for October, with a year-on-year decrease of 3%, contrasting sharply with a 6.8% increase in September [1] Industry Summary - The hospital channel experienced a year-on-year decline of 3.3%, down from a previous growth of 7.1% [1] - The retail channel remained nearly flat year-on-year, showing a notable slowdown from a 2.4% increase in September [1] Company Performance - The performance of China's biopharmaceutical products in October showed a mixed trend, with core products anlotinib and glycyrrhizic acid seeing year-on-year sales growth of 6.5% and 4.4%, respectively [1] - Conversely, sales of budesonide and esomeprazole fell significantly, with year-on-year declines of 28.5% and 39.4%, respectively [1] Revenue Forecast Adjustments - Based on the sales performance, the company has revised its revenue forecasts for 2026 and 2027 downwards by 0.2% and 0.4%, respectively [1] - The target price has been adjusted from HKD 9.4 to HKD 8.3, while maintaining a "Buy" rating due to the substantial licensing potential of pipeline products [1] Specific Company Ratings - For CSPC Pharmaceutical, the report notes continued poor sales performance of several key drugs in October, leading to a maintained "Underperform" rating with a target price of HKD 7.2 [1]

冲高回落，临近尾盘出现拉升，最终小涨0.43%。恒生科技涨幅居前，银行、大消费、互联网等紧随其 后，恒生医疗逆势回撤。 恒生医疗开盘后直线跳水，随后全天震荡下行，截至收盘下跌1.02%。其中药明生物下跌2.99%，药明生 物下跌2.6%，信达生物、康方生物、翰森制药、中国生物等股均小幅收跌；京东健康逆势大涨3.3%。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 恒生科技高开低走后全天弱势，截至收盘上涨0.55%，中芯国际大涨5.92%，百度集团上涨1.26%，京东 集团、阿里巴巴、快手、美团等股均小幅收涨；小米集团逆势小跌1.83%，网易下跌0.09%。 银行股全天维持在中轴上方窄幅盘整，截至收盘上涨0.43%。其中汇丰控股上涨1.68%，中银香港上涨 1.67%，大新银行上涨1.13%；民生银行逆势小跌1.48%，邮储银行、郑州银行、交通银行等股均小幅收 跌。 ...

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is experiencing a rebound, with significant trading activity and price increases among leading innovative drug companies, indicating a positive shift in market sentiment towards this sector [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect innovative drug ETF (520880) reached a peak increase of 1.53% and traded over 140 million yuan during the session [1]. - Leading companies in the innovative drug sector, such as CSPC Pharmaceutical Group, recorded gains exceeding 5%, while others like 3SBio and Hengrui Medicine saw increases of over 2% [1]. Group 2: Investment Insights - Analysts from Zhongtai Securities noted that the current innovative drug market differs from the 2019-2021 period, as the sector is transitioning from narrative to actual performance, with trading volumes hitting new highs [1]. - Long-term support from domestic policies for innovative drugs is evident, with the introduction of commercial insurance directories enhancing payment capabilities [1][3]. - Changjiang Securities emphasized the emergence of a new policy support cycle for the pharmaceutical industry, particularly for innovative drugs, suggesting a focus on high-quality assets with strong overseas potential [3]. Group 3: ETF Characteristics - The Hong Kong Stock Connect innovative drug ETF (520880) is designed to track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three key advantages: it exclusively includes innovative drug companies, has a high concentration of leading firms, and employs risk control measures for less liquid stocks [3][4]. - The top ten holdings in the ETF account for over 72% of its weight, showcasing the dominance of leading innovative drug companies [4]. Group 4: Alternative Investment Options - For investors seeking to mitigate volatility while still focusing on innovative drugs, the only ETF in the market (562050) offers a mix of innovative and traditional Chinese medicine stocks, providing a balanced approach [4].

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is experiencing a rebound, with significant trading activity and price increases among leading innovative drug companies, indicating a shift in the market dynamics for innovative pharmaceuticals in China [1][3]. Group 1: Market Performance - On December 23, the Hong Kong Stock Connect innovative drug ETF (520880) reached a peak increase of 1.53% and recorded over 1.4 billion yuan in trading volume [1]. - Leading companies in the innovative drug sector, such as CSPC Pharmaceutical Group, saw stock price increases exceeding 5%, while others like 3SBio and Hengrui Medicine rose over 2% [1]. Group 2: Investment Insights - Analysts from Zhongtai Securities noted that the current innovative drug market differs from the 2019-2021 period, as it has transitioned from narrative to actual performance, with trading volumes hitting new highs, reflecting a leap in China's innovative capabilities [1]. - Changjiang Securities emphasized that the innovative drug sector is entering a new cycle of policy support, suggesting a focus on high-quality innovative drug assets with strong overseas potential [3]. Group 3: ETF Characteristics - The Hong Kong Stock Connect innovative drug ETF (520880) tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: it exclusively includes innovative drug companies, has a high concentration of leading firms (over 72% in the top ten), and employs measures to control risks associated with less liquid stocks [3][4]. - The ETF's current market price is close to its initial listing price, presenting a potential value opportunity for investors [3]. Group 4: Composition and Strategy - The top ten holdings of the Hong Kong Stock Connect innovative drug ETF account for 72.57% of the total weight, showcasing significant dominance by leading companies in the sector [4]. - For investors seeking to mitigate volatility while still focusing on innovative drugs, alternative ETFs that include a mix of traditional Chinese medicine and innovative drugs are available, providing a balanced investment approach [4].

Group 1 - The core viewpoint of the report is that the recent pullback in the pharmaceutical sector is primarily due to the digestion and rebalancing of valuations and expectations, which creates a better investment window for future opportunities [1] - Looking ahead to 2026, the trend of innovative drugs going overseas is expected to continue, with a focus on the clinical progress and data validation of pipelines that have already entered international markets [1] - The impact of the recently signed U.S. Biosecurity Act on Chinese CXO companies is anticipated to be limited, as it does not affect Medicaid and Medicare procurement and has clear definitions regarding related parties, along with the relatively small revenue contribution from U.S. administrative agencies to Chinese CXO firms [1] Group 2 - The industry outlook suggests a more conservative investment approach, emphasizing opportunities in undervalued stocks [1] - Recommended stocks for investment include 3SBio, Genscript Biotech, WuXi AppTec, and China National Pharmaceutical Group [1]

盐酸安罗替尼胶囊（福可维 ）是中国生物制药核心企业正大天晴历时十余年自主研发的1类创新药，其化合物专利荣获"中国专利金奖"。 【导读】安罗替尼境外"仿制药"为假药 2018年上映的电影《我不是药神》，现在有了一个完全不一样的现实版本，这次真的"不是药神"。 12月22日下午，央视新闻曝光了一起代购的境外抗癌药有效成分为0的"假药案"，此事一度登上百度热搜榜第一。 于是，药品生产企业通过网络渠道购买了这种所谓的"境外版本药"进行研究。经检测发现，该版本药品中安罗替尼的含量为0，即"境外版"安罗替尼本质 上是完全没有有效成分的假药。 公安机关经初步侦查发现，这些药都是由背包客通过人身携带的方式，从境外携带到广州，再集中向全国发货。 该药物在国内流通后，因下游层层加价，一般患者购买的价格在1500元左右一盒，每盒的药量是正版的三倍。大量患者家属对警方表示，这款所谓的"救 命药"并没有明确的治疗效果。 公安机关将患者家属提供的剩余药品送至鉴定机构检测，鉴定结论和上述药企的结论一致，即该安罗替尼"仿制药"中未检出安罗替尼成分。由此，连云港 市市场监督管理局认定，涉案相关药品可以认定为假药。 自2018年获批上市以来，安 ...